OBJECTIVE: To report a cohort of children with periodic fever syndromes (PFS) from Southeast Michigan. METHODS: A retrospective review of medical records for patients referred for periodic fever over 5 years. RESULTS: Sixty-six patients including 21 FMF, 15 PFAPA, four TRAPS and one patient with combined HIDS and FMF were included. In addition, 25 patients were categorized as clinical PFS (cPFS) based on their clinical features however their genetic workup was either negative or inconclusive. Majority of the patients with FMF were from Middle Eastern background (88 %), but positive family history was noted in only 55 % of cases. Mean age at diagnosis was 40.8 months with a mean delay in diagnosis of 24 months. Most common MEFV mutations were p.M694V and p.M694I. Four patients with TRAPS were from mixed European descent and age at onset of symptoms was 6, 12, 12, and 84 months respectively. TNFRSF1A sequence variants in the TRAPS patients included p.R121Q (R92Q) and p.C99G (C70G); one patient had a rare occurrence of a concurrent p.V726A/-MEFV mutation. One patient with HIDS and FMF presented with atypical overlapping PFS clinical manifestations and genetic evaluation showed a unique combination of p.I268T/p.V377I MVK mutations and p.E230K/-MEFV variant. All patients with PFAPA group were from mixed European descent, symptoms started at a mean age of 34.6 months with a mean delay in diagnosis of 23.3 months. Symptoms started during infancy in six patients. All patients fulfilled the diagnostic criteria for PFAPA. The mean age of onset of symptoms in cPFS group was 17.2 months. Empiric colchicine and glucocorticosteroids controlled flares in majority of patients with cPFS. No evidence of amyloidosis was found in this entire cohort of 66 patients after a mean of 29.2 months of follow-up. CONCLUSION: PFS can present with atypical manifestations and should not be excluded based on a negative family history. Concomitant mutations in different autoinflammatory disorders genes can be present and possibly explain atypical manifestations. Various therapies may be considered even if genetic testing is inconclusive or negative.
OBJECTIVE: To report a cohort of children with periodic fever syndromes (PFS) from Southeast Michigan. METHODS: A retrospective review of medical records for patients referred for periodic fever over 5 years. RESULTS: Sixty-six patients including 21 FMF, 15 PFAPA, four TRAPS and one patient with combined HIDS and FMF were included. In addition, 25 patients were categorized as clinical PFS (cPFS) based on their clinical features however their genetic workup was either negative or inconclusive. Majority of the patients with FMF were from Middle Eastern background (88 %), but positive family history was noted in only 55 % of cases. Mean age at diagnosis was 40.8 months with a mean delay in diagnosis of 24 months. Most common MEFV mutations were p.M694V and p.M694I. Four patients with TRAPS were from mixed European descent and age at onset of symptoms was 6, 12, 12, and 84 months respectively. TNFRSF1A sequence variants in the TRAPS patients included p.R121Q (R92Q) and p.C99G (C70G); one patient had a rare occurrence of a concurrent p.V726A/-MEFV mutation. One patient with HIDS and FMF presented with atypical overlapping PFS clinical manifestations and genetic evaluation showed a unique combination of p.I268T/p.V377IMVK mutations and p.E230K/-MEFV variant. All patients with PFAPA group were from mixed European descent, symptoms started at a mean age of 34.6 months with a mean delay in diagnosis of 23.3 months. Symptoms started during infancy in six patients. All patients fulfilled the diagnostic criteria for PFAPA. The mean age of onset of symptoms in cPFS group was 17.2 months. Empiric colchicine and glucocorticosteroids controlled flares in majority of patients with cPFS. No evidence of amyloidosis was found in this entire cohort of 66 patients after a mean of 29.2 months of follow-up. CONCLUSION: PFS can present with atypical manifestations and should not be excluded based on a negative family history. Concomitant mutations in different autoinflammatory disorders genes can be present and possibly explain atypical manifestations. Various therapies may be considered even if genetic testing is inconclusive or negative.
Authors: M F McDermott; I Aksentijevich; J Galon; E M McDermott; B W Ogunkolade; M Centola; E Mansfield; M Gadina; L Karenko; T Pettersson; J McCarthy; D M Frucht; M Aringer; Y Torosyan; A M Teppo; M Wilson; H M Karaarslan; Y Wan; I Todd; G Wood; R Schlimgen; T R Kumarajeewa; S M Cooper; J P Vella; C I Amos; J Mulley; K A Quane; M G Molloy; A Ranki; R J Powell; G A Hitman; J J O'Shea; D L Kastner Journal: Cell Date: 1999-04-02 Impact factor: 41.582
Authors: Jeroen C H van der Hilst; Evelien J Bodar; Karyl S Barron; Joost Frenkel; Joost P H Drenth; Jos W M van der Meer; Anna Simon Journal: Medicine (Baltimore) Date: 2008-11 Impact factor: 1.889
Authors: Alexandra-Chloé Villani; Mathieu Lemire; Edouard Louis; Mark S Silverberg; Catherine Collette; Geneviève Fortin; Elaine R Nimmo; Yannick Renaud; Sébastien Brunet; Cécile Libioulle; Jacques Belaiche; Alain Bitton; Daniel Gaudet; Albert Cohen; Diane Langelier; John D Rioux; Ian D R Arnott; Gary E Wild; Paul Rutgeerts; Jack Satsangi; Séverine Vermeire; Thomas J Hudson; Denis Franchimont Journal: PLoS One Date: 2009-09-28 Impact factor: 3.240
Authors: Kalpana Manthiram; Suzanne C Li; Jonathan S Hausmann; Gil Amarilyo; Karyl Barron; Hanna Kim; Simona Nativ; Geraldina Lionetti; Andrew Zeft; Donald Goldsmith; David Kimberlin; Kathryn Edwards; Fatma Dedeoglu; Sivia Lapidus Journal: Rheumatol Int Date: 2017-03-07 Impact factor: 2.631
Authors: Carlo De Pieri; Josef Vuch; Eleonora De Martino; Anna M Bianco; Luca Ronfani; Emmanouil Athanasakis; Barbara Bortot; Sergio Crovella; Andrea Taddio; Giovanni M Severini; Alberto Tommasini Journal: Pediatr Rheumatol Online J Date: 2015-04-10 Impact factor: 3.054
Authors: Jasmin Beate Kuemmerle-Deschner; Raju Gautam; Aneesh Thomas George; Syed Raza; Kathleen Graham Lomax; Peter Hur Journal: RMD Open Date: 2020-07
Authors: Susanne M Benseler; Jasmin B Kuemmerle-Deschner; Tatjana Welzel; Anna L Wildermuth; Norbert Deschner Journal: Pediatr Rheumatol Online J Date: 2021-09-14 Impact factor: 3.054